Official Title
STUDY ECMO-COVID-19 : PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2
Brief Summary

Describe COVID-19 patients who are receiving ECMO-VV respiratory replacement and what happens to them.

Status
Recruiting
Conditions
Respiratory Distress Syndrome
Eligibility Criteria

Inclusion Criteria:

- Patient over the age of 18;

- Diagnostic COVID-19 by RT-PCR;

- Hospitalisation in resuscitation for the management of complications related to COVID-19

- Implanted ECMO-VV during hospitalisation;

- Patient agreeing to participate in the study

Exclusion Criteria:

- Sujet under guardianship or trusteeship

- Sujet under safeguard of justice

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
France
Contacts

Pierre-Emmanuel FALCOZ, MD, PhD
33 3 69 55 11 34
pierre-emmanuel.falcoz@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR
33 3 88 11 66 90
said.chayer@chru-strasbourg.fr

Investigators

Pierre-Emmanuel FALCOZ, MD, PhD
Study Director
Service de Chirurgie Thoracique Nouvel Hôpital Civl Hôpitaux Univesitaires de Strasbourg

Sponsors / Collaborators
University Hospital, Strasbourg, France
NCT Number
NCT04343404
Keywords
Respiratory Distress Syndrome
ARDS
SARS-CoV-2
Extracorporeal membrane oxygenation
ECMO
Veno-venous ECMO
MeSH Terms
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Adult